Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Bleeding Esophageal Varices Clinical Trial

Official title:
Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Status Active, not recruiting

Clinical Trial Summary

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices ;

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03624517` - Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices	Phase 4
Completed	`NCT02475122` - Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR)	N/A
Completed	`NCT01095185` - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding	Phase 3
Recruiting	`NCT02853526` - TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV	Phase 3
Recruiting	`NCT01970748` - Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices	Phase 4